GSK's hepatitis B treatment, Hibsago (bepirovirsen), received FDA approval for adults with chronic hepatitis B without cirrhosis, supporting Jefferies' forecast of peak annual sales at £2.2 billion. The drug offers a potential functional cure, allowing some patients to stop long-term antiviral therapy, a significant advance over existing treatments. However, the treatment requires intensive safety monitoring due to risks like liver inflammation and low platelet counts, which could limit its commercial adoption. Jefferies highlights that the key challenge now is execution and market uptake, with potential for future combination therapies to expand patient benefits.
GSK shares are currently trading at USD 50.18 on Pluang, down 0.89% for the day, showing steady investor interest with 100% buy orders as of Oct 21, 2026 19:51 WIB. The stock maintains a dividend yield of 3.59%, reflecting ongoing value for shareholders amid the new drug approval news.
HUTCHMED has finalized an exclusive license agreement with GSK granting GSK rights to develop and commercialize HMPL-A830, a novel KRAS-EGFR antibody conjugate therapy, outside China, Hong Kong, Macau, and Taiwan. This therapy targets cancers with KR...
The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response ...
Jefferies has upgraded GSK PLC to a 'buy' rating with a 2,500p price target, suggesting a 34% gain from recent levels. This follows positive results from the EMBOLD trial of GSK's experimental lung cancer drug ris-rez, which showed a 61% tumor respon...
GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This respo...
